Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides.

Molecular Cancer Therapeutics
Jamie V ShiahDaniel E Johnson

Abstract

STAT3 has been recognized for its key role in the progression of cancer, where it is frequently upregulated or constitutively hyperactivated, contributing to tumor cell proliferation, survival, and migration, as well as angiogenesis and suppression of antitumor immunity. Given the ubiquity of dysregulated STAT3 activity in cancer, it has long been considered a highly attractive target for the development of anticancer therapies. Efforts to target STAT3, however, have proven to be especially challenging, perhaps owing to the fact that transcription factors lack targetable enzymatic activity and have historically been considered "undruggable." Small-molecule inhibitors targeting STAT3 have been limited by insufficient selectivity and potency. More recently, therapeutic approaches that selectively target STAT3 protein for degradation have been developed, offering novel strategies that do not rely on inhibition of upstream pathways or direct competitive inhibition of the STAT3 protein. Here, we review these emerging approaches, including the development of STAT3 proteolysis targeting chimera agents, as well as preclinical and clinical studies of chemically stabilized antisense molecules, such as the clinical agent AZD9150. These th...Continue Reading

References

Aug 24, 1999·Cell·J F BrombergJ E Darnell
Apr 13, 2000·Proceedings of the National Academy of Sciences of the United States of America·J R GrandisJ D Kim
Jul 5, 2001·Proceedings of the National Academy of Sciences of the United States of America·K M SakamotoR J Deshaies
Jul 2, 2003·The Journal of Biological Chemistry·Jutta BraunsteinChristian Schindler
Feb 18, 2004·Nature Reviews. Cancer·Hua Yu, Richard Jove
Oct 8, 2004·Expert Opinion on Therapeutic Targets·James Turkson
Oct 29, 2004·The American Journal of Pathology·Charles V Clevenger
Jun 7, 2005·Nature Medicine·James E Darnell
Nov 8, 2006·International Journal of Colorectal Disease·AiPing BaiXiang Gao
Dec 23, 2006·Nature Reviews. Immunology·Hua YuDrew Pardoll
Jul 31, 2007·Journal of Cellular Biochemistry·Kelly M QuesnelleJennifer R Grandis
Feb 7, 2009·Nature Reviews. Immunology·Dmitry I Gabrilovich, Srinivas Nagaraj
Jun 27, 2009·Science·Daniel J GoughDavid E Levy
Jun 3, 2010·Current Topics in Microbiology and Immunology·Heehyoung LeeHua Yu
Mar 29, 2011·Molecular Interventions·Paul A Johnston, Jennifer R Grandis
Mar 2, 2012·The Journal of Biological Chemistry·Olga A TimofeevaAnatoly Dritschilo
Jul 24, 2012·Current Opinion in Pharmacology·Apostolos KontziasJohn J O'Shea
Jan 5, 2013·Proceedings of the National Academy of Sciences of the United States of America·Olga A TimofeevaAnatoly Dritschilo
Jul 13, 2013·The Oncologist·Elizabeth R PlimackS Gail Eckhardt
Nov 29, 2013·Journal of Hematology & Oncology·Zhi-Yuan QiuJian-Yong Li
Aug 16, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chi Young OkKen H Young
Feb 24, 2015·Journal of Neuro-oncology·Sherise D FergusonAmy B Heimberger
Jun 16, 2015·Nature Chemical Biology·Daniel P BondesonCraig M Crews
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Herbert I HurwitzRichard S Levy
Nov 26, 2015·Angewandte Chemie·Ashton C LaiCraig M Crews
Dec 10, 2015·Molecular Carcinogenesis·Jaya Srivastava, John DiGiovanni
Jul 29, 2016·Oncoimmunology·Guido KroemerLaurence Zitvogel
Sep 11, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Helena A YuJacqueline Bromberg
Oct 13, 2016·Annual Review of Pharmacology and Toxicology·C Frank BennettRichard S Geary
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Seiichi OdateCarol J Thiele
Nov 26, 2016·Nature Reviews. Drug Discovery·Ashton C Lai, Craig M Crews
Mar 1, 2017·Nature Biotechnology·Anastasia Khvorova, Jonathan K Watts

❮ Previous
Next ❯

Citations

Sep 2, 2021·Bioactive Materials·Lei WuJun Yue

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.